Case Report Supports Use of Xeljanz in Children with Systemic JIA
News
Xeljanz (tofacitinib) might be an effective and safe treatment for children with systemic juvenile idiopathic arthritis (JIA), a new case report suggests. The study, “Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic ... Read more